Exact Sciences to Acquire Thrive Earlier Detection
Exact Sciences Corp. and Thrive Earlier Detection Corp. entered into a definitive agreement under which Exact Sciences will acquire Thrive.
© 2024 DCF Group.
All Rights Reserved.
Entries by raincastle
Foghorn Therapeutics Announces Pricing of Initial Public Offering
Foghorn Therapeutics announced the pricing of its initial public offering of 7.50 million shares of its common stock.
C4 Therapeutics Raises $182 Million in Upsized IPO
C4 Therapeutics priced its upsized initial public offering at $19 per share for gross proceeds of $182.4 million.
Oncorus Announces Pricing of Initial Public Offering
Clinical-stage biopharmaceutical company announced the pricing of its IPO of 5.8 million shares of common stock.
Relay Therapeutics Announces Closing of Initial Public Offering
Clinical-stage precision medicine company announced the closing of its IPO of 23 million shares of its common stock.
Generation Bio Announces Closing of Initial Public Offering
Genetic medicines company announced the closing of its initial public offering of 12,105,263 shares of common stock.
Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline
Cullinan Oncology announced Series B funding of $98.5 million, adding financial backing from institutional investors and family offices.
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Gene editing biotech Beam Therapeutics raised $180 million in its IPO after offering 48% more shares than anticipated.
Black Diamond Therapeutics Doubles After $201 Million IPO
Black Diamond Therapeutics Inc. more than doubled in its trading debut after raising $201 million in an IPO that exceeded its goals.